Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker TLSA · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Nov 12, 2026 | A Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients NCT06292923 · Secondary Progressive Multiple Sclerosis Foralumab, Placebo | TLSA Tiziana Life Sciences Ltd | Phase 2 | Completed was active, not recruiting | 54 | Sep 17, 2026 | Registry ↗ |
| Oct 28, 2026 | The BANYAN Trial, an ALS MyMatch Trial Evaluating Safety, Biomarker Activity, and Microglial Activa… NCT07688239 · ALS (Amyotrophic Lateral Sclerosis), ALS - Amyotrophic Late… Foralumab Nasal, Placebo | TLSA Tiziana Life Sciences Ltd | Phase 2 | Enrolling by invitation | 44 | Jul 2027 | Registry ↗ |
| Jun 10, 2026 | A Phase 2a Study of Foralumab Nasal in Patients With Multiple System Atrophy (MSA) NCT06868628 · Multiple System Atrophy Foralumab Nasal | TLSA Tiziana Life Sciences Ltd | Phase 2 | Recruiting | 5 | Apr 1, 2027 | Registry ↗ |
| Jun 6, 2025 | Nasal Foralumab in Patients With Non-Active Secondary Progressive Multiple Sclerosis NCT06890923 · Non-Active Secondary Progressive Multiple Sclerosis Foralumab TZLS-401 100 µg | TLSA Tiziana Life Sciences Ltd | Phase 2 | Recruiting | 55 | Apr 30, 2026 | Registry ↗ |
| Jun 6, 2025 | Intermediate-Size Patient Population Expanded Access: Foralumab in Non-Active Secondary Progressive… NCT06802328 · Non-Active Secondary Progressive Multiple Sclerosis Foralumab TZLS-401 50 µg | TLSA Tiziana Life Sciences Ltd | — | Available | — | — | Registry ↗ |
| Mar 17, 2025 | Safety, Tolerability and Immune Effects of the Nasal Foralumab in Healthy Human Volunteers NCT06879067 · Safety, Tolerability Placebo, Foralumab Nasal | TLSA Tiziana Life Sciences Ltd | Phase 1 | Completed | 27 | Jul 23, 2019 | Registry ↗ |
| Dec 15, 2022 | Milciclib in Combination With Gemcitabine in Advanced NSCLC NCT05651269 · NSCLC Milciclib Dose: 150 mg/day Mode of administration: oral | TLSA Tiziana Life Sciences Ltd | Phase 2 | Unknown | 28 | Dec 2024 | Registry ↗ |
| Oct 20, 2022 | A Study of Oral Foralumab in Participants With Moderate to Severely Active Crohn's Disease NCT05028946 · Crohn's Disease Foralumab | TLSA Tiziana Life Sciences Ltd | Phase 1 | Withdrawn | 0 | Jul 7, 2023 | Registry ↗ |
| Oct 19, 2022 | In-patient COVID-19 Study of Intranasal Foralumab NCT04983446 · Covid19, COVID-19 Lower Respiratory Infection Foralumab, Placebo | TLSA Tiziana Life Sciences Ltd | Phase 2 | Withdrawn | 0 | Oct 30, 2022 | Registry ↗ |
| Mar 3, 2022 | Phase 1b Multiple Ascending Dose Study of Foralumab in Primary and Secondary Progressive MS NCT05029609 · Primary Progressive Multiple Sclerosis, Secondary Progressi… Intranasal Foralumab Solution, Placebo | TLSA Tiziana Life Sciences Ltd | Phase 1 | Withdrawn | 0 | Nov 2022 | Registry ↗ |
| Oct 12, 2021 | Study of Milciclib in Patients With Unresectable/Metastatic Hepatocellular Carcinoma NCT03109886 · Hepatocellular Carcinoma Milciclib maleate | TLSA Tiziana Life Sciences Ltd | Phase 2 | Completed | 31 | May 16, 2019 | Registry ↗ |
| Sep 12, 2019 | Assessment of the Safety of Foralumab, an Oral Anti-CD3 Antibody, in Patients With NASH and T2DM NCT03291249 · NASH - Nonalcoholic Steatohepatitis, NAFLD Foralumab, placebo | TLSA Tiziana Life Sciences Ltd | Phase 2 | Withdrawn | 0 | Dec 1, 2018 | Registry ↗ |
| Feb 6, 2019 | Study Of Oral PHA-848125AC In Patients With Malignant Thymoma Previously Treated With Multiple Line… NCT01301391 · Malignant Thymoma Milciclib Maleate | TLSA Tiziana Life Sciences Ltd | Phase 2 | Terminated | 30 | May 31, 2017 | Registry ↗ |
| Feb 6, 2019 | Phase II Study Of Oral PHA-848125AC In Patients With Thymic Carcinoma NCT01011439 · Thymic Carcinoma Milciclib Maleate | TLSA Tiziana Life Sciences Ltd | Phase 2 | Terminated | 72 | May 31, 2017 | Registry ↗ |
14 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 6:15 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances